DUBLIN--(BUSINESS WIRE)--The "In-Vitro Toxicology/Toxicity Testing Market by Product & Services, Toxicity Endpoint & Test (Carcinogenicity, Dermal Toxicity), Technology (Cell-based, HTS), Method (Cellular Assays), Industry (Pharmaceutical, Cosmetics), Region-Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.
The In-Vitro Toxicology Testing Market is Expected to Reach USD 12.7 Billion by 2024 from an Estimated USD 8.1 Billion in 2019, at a CAGR of 9.3%.
The opposition to animal testing, technological advancements, and increasing R&D expenditure to detect toxicity at an early stage during drug development are the primary growth factors for this industry.
The increasing focus of the pharmaceutical and cosmetics industries on using in-vitro methods for product testing along with the improvement in silico methods for predictive toxicology studies are expected to offer significant growth opportunities for players in this market. However, the dearth of skilled professionals is a substantial market challenge.
The software segment is expected to grow at the highest rate during the forecast period.
Based on the product & service, the in-vitro toxicology testing market is segmented into consumables, assays, equipment, software, and services. The software segment is projected to witness the highest growth in the in-vitro toxicology testing market during the forecast period.
Growth in this segment is driven mostly by the rising number of new technologies to develop in-vitro signatures and computational models capable of predicting in vivo responses. Also, the increasing use of the latest software in the industry and the academia to predict toxicity by comparing the data of new substances with other structurally or biologically similar compounds, are expected to drive the growth of this segment.
The ADME segment is expected to account for the largest market share in 2018.
Based on toxicity endpoints & tests undertaken across all industries, the in-vitro toxicity testing market is segmented into ADME; skin irritation, corrosion, and sensitization; genotoxicity; cytotoxicity; ocular toxicity; organ toxicity; phototoxicity; dermal toxicity; and other endpoints & tests. The ADME segment accounted for the largest share of the in-vitro toxicity testing market in 2018. This can be attributed to the high adoption during the drug development process with the advantage of producing highly reproducible & accurate data.
Toxicogenomics is expected to grow at the highest rate during the forecast period.
The toxicogenomics segment is expected to grow at the highest CAGR during the forecast period, primarily due to the technological advancements taking place in the field of proteomics and genomics. Also, the improvements in proteomic technologies are enhancing the study of gene & protein activity during toxicity analysis. Technological advancements taking place in the field of proteomics and genomics will further drive the growth of this segment in the coming years.
Europe is expected to hold the largest share for players operating in the in-vitro toxicology testing market.
Europe accounted for the largest share of the in-vitro toxicology testing market in 2018. Factors such as high adoption of in-vitro toxicology testing assays and services in the cosmetics and chemical industries after the ban on animal testing in the region are among the few factors expected to contribute to the growth of this market.
Key Topics Covered:
2 Research Methodology
3 Executive Summary
4 Premium Insights
4.1 In Vitro Toxicology Testing Market Overview
4.2 Asia Pacific: Market, By Method
4.3 Market: Geographic Growth Opportunities
4.4 Market, By Region (2017-2024)
4.5 Market: Developed vs Developing Markets
5 Market Overview
5.2 Market Dynamics
5.2.1 Market Drivers
18.104.22.168 Opposition to Animal Testing
22.214.171.124 Technological Advancements
126.96.36.199 R&D Toward Early Stage Toxicity Detection
5.2.2 Market Restraints
188.8.131.52 Reluctance of Regulatory Authorities to Consider Alternative Methods for Proving Safety and Efficacy
184.108.40.206 Failure to Establish the Intricacies of in Vivo Conditions, In Vitro
220.127.116.11 Lack of In Vitro Models to Study Complex Endpoints
5.2.3 Market Opportunities
18.104.22.168 Increasing Focus on Drug Discovery and Personalized Medicine Using In Vitro Methods
22.214.171.124 Increasing Number of Toxicology Databases
5.2.4 Market Challenges
126.96.36.199 Dearth of Skilled Professionals
6 Industry Insights
6.2 Industry Trends
6.2.1 Increasing Focus on Predictive Toxicology
6.3 Supply Chain Analysis
6.4 Regulatory Committee Activities
6.4.1 Major Stakeholders
6.4.2 Key Influencers
7 In Vitro Toxicology Testing Market, By Product & Service
7.2.1 Consumables to Dominate the Market During the Forecast Period
7.3.1 Bacterial Toxicity Assays
188.8.131.52 Bacterial Assays Dominate the Market as They Form the Most Widely Adopted Assay Type Across Industries
7.3.2 Enzyme Toxicity Assays
184.108.40.206 Enzyme Toxicity Assays are Being Increasingly Used for Endocrine-Disrupting Studies
7.3.3 Cell-Based Elisa & Western Blots
220.127.116.11 Cell-Based Assays are Cost-Effective and Witnessing Increasing Adoption in Drug Discovery
7.3.4 Receptor-Binding Assays
18.104.22.168 Receptor-Binding Assays are Well-Suited for High-Throughput Formats
7.3.5 Tissue Culture Assays
22.214.171.124 Tissue Culture Assays Offer the Advantage of Mimicking in Vivo Tissue Architecture
7.3.6 Other Assays
7.4.1 Fully Automated Equipment is Witnessing Growing Adoption in Research
7.5.1 Software Tools are Vital in Reducing Analysis Times and Managing Large Amounts of Data Generated in Operations
7.6.1 Lack of Infrastructure and Expertise have Driven Reliance on Service Providers
8 In Vitro Toxicology Testing Market, By Toxicity Endpoints & Tests
8.2 ADME (Absorption, Distribution, Metabolism, & Excretion)
8.2.1 ADME to Dominate the In Vitro Toxicity Testing Market During the Forecast Period
8.3 Skin Irritation, Corrosion, & Sensitization
8.3.1 This Toxicity Endpoint is Widely Studied in the Cosmetic Industry
8.4 Genotoxicity Testing
8.4.1 Genotoxic Assessment Forms an Integral Part in the Pre-Clinical Drug Development Process
8.5 Cytotoxicity Testing
8.5.1 Cytotoxic Tests are Majorly Done on Cancer and Non-Cancer Cell Lines
8.6 Ocular Toxicity
8.6.1 In Vitro and EX Vivo Methods are Gaining High Recognition for Ocular Toxicity Testing
8.7 Organ Toxicity
8.7.1 High-Content Screening and Cell-Based Assays are Used to Detect Organ-Specific Toxicity
8.8 Phototoxicity Testing
8.8.1 Validated Non-Animal Methods are Used to Evaluate Photosafety of Cosmetics, Pharmaceuticals, & Chemicals
8.9 Dermal Toxicity
8.9.1 In Vitro Methods for Dermal Toxicity Testing is Expected to Gain Recognition in the Coming Years
8.10 Other Toxicity Endpoints & Tests
9 In Vitro Toxicology Testing Market, By Technology
9.2 Cell Culture Technologies
9.2.1 Cell- & Tissue-Based Technologies are the Most Widely Adopted in In Vitro Testing
9.3 High-Throughput Technologies
9.3.1 Increasing Use of High-Content Imaging Technologies is Driving Market Growth
9.4.1 Improvements in Proteomic Technologies are Enhancing the Study of Gene & Protein Activity During Toxicity Analysis
10 In Vitro Toxicology Testing Market, By Industry
10.2 Pharmaceuticals & Biopharmaceuticals
10.2.1 Drug Attrition Rate is Leading to the High Adoption of In Vitro Testing Assays in the Early Stages of Drug Development
10.3 Cosmetics & Household Products
10.3.1 Ban on Animal Testing is Increasing the Adoption of In Vitro Assays for Safety Testing
10.4.1 Increasing Focus on Food Safety is Driving Market Growth
10.5.1 Increasing Focus on Organoid-Based In Vitro Approaches for Chemical Testing is Propelling the Market
11 In Vitro Toxicology Testing Market, By Method
11.2 Cellular Assays
11.2.1 Development of Multi-Parameter Assays Will Provide Significant Growth Opportunities to Market Players
11.3 Biochemical Assays
11.3.1 Assays are Majorly Used in the Pharmaceutical Industry to Quantify Biological Activities in Drug Development
11.4 In Silico Models
11.4.1 In Silico Models are Expected to Register the Highest CAGR During the Forecast Period
11.5 EX Vivo Models
11.5.1 EX Vivo Models are Widely Used in Skin & Eye Toxicity Testing in the Cosmetic Industry
12 In Vitro Toxicology Testing Market, By Region
13 Competitive Landscape
14 Company Profiles
- Bio-Rad Laboratories, Inc.
- Catalent, Inc.
- Charles River Laboratories International, Inc.
- Covance, Inc.
- Creative Bioarray
- Creative Biolabs
- Cyprotex PLC
- Eurofins Scientific Se
- GE Healthcare
- Gentronix Limited
- GVK Biosciences Private Limited
- MB Research Laboratories
- Merck KGaA
- Promega Corporation
- Qiagen N.V.
- SGS S.A.
- Shanghai Medicilon Inc.
- Thermo Fisher Scientific, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/gzcnm8